Evidence map›Paper›PMID 38616954›Full record

ArticleProteoglycan research2024

In vivo activities of heparan sulfate differentially modified by NDSTs during development.

Eriko Nakato, Sarah Baker, Akiko Kinoshita-Toyoda, Collin Knudsen, Yi-Si Lu, Masahiko Takemura, Hidenao Toyoda, Hiroshi Nakato

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteoglycan research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Eriko NakatoDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
Sarah BakerDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
Akiko Kinoshita-ToyodaFaculty of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Collin KnudsenDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-8250-3474
Yi-Si LuDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
Masahiko TakemuraDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
Hidenao ToyodaFaculty of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Hiroshi NakatoDepartment of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · USRitsumeikan University · JP

Funding

Heparan sulfate proteoglycans in signaling and developmentR35GM131688 · NIGMS · UNIVERSITY OF MINNESOTA · PI Hiroshi Nakato · 2019 to 2026
$2.6M
NIGMS NIH HHS R35 GM131688
6 · The paper itself

Abstract

Heparan sulfate proteoglycans (HSPGs) serve as co-receptors for growth factor signaling during development. It is well known that the level and patterns of sulfate groups of heparan sulfate (HS) chains, or HS fine structures, have a major impact on HSPG function. On the other hand, the physiological significance of other structural features of HS, including NS/NA domain organization, remains to be elucidated. A blueprint of the HS domain structures is mainly controlled by HS

Indexed as

developmentDrosophilaheparan sulfatemorphogenesisN-deacetylase/N-sulfotransferase (NDST)

Identifiers

PMID38616954
PMCPMC11011245
OpenAlexW4391982106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.